Drug
Azacitidine or decitabine
Azacitidine or decitabine is a pharmaceutical drug with 2 clinical trials. Currently 1 active trials ongoing.
Total Trials
2
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Active Trials
1(50%)
Phase Distribution
Ph phase_2
2
100%
Phase Distribution
0
Early Stage
2
Mid Stage
0
Late Stage
Phase Distribution2 total trials
Phase 2Efficacy & side effects
2(100.0%)
Highest Phase Reached
Phase 2Trial Status & Enrollment
Completion Rate
0.0%
0 of 1 finished
Non-Completion Rate
100.0%
1 ended early
Currently Active
1
trials recruiting
Total Trials
2
all time
Status Distribution
Active(1)
Terminated(1)
Detailed Status
Recruiting1
Withdrawn1
Development Timeline
Analytics
Development Status
Total Trials
2
Active
1
Success Rate
N/A
Most Advanced
Phase 2
Trials by Phase
Phase 22 (100.0%)
Trials by Status
recruiting150%
withdrawn150%
Recent Activity
1 active trials
Showing 2 of 2
withdrawnphase_2
Trial of Cladribine and Low-Dose Cytarabine (LoDAC) Alternating With Decitabine vs. Hypomethylating Agents (HMA) Plus Venetoclax as Frontline Therapy for AML or High-Grade MDS in Patients Unfit for Intensive Induction
NCT05766514
recruitingphase_2
Hypomethylating Agent and Venetoclax After Allo-HSCT in Patients With High-risk Myeloid Malignancies.
NCT05841771
Clinical Trials (2)
Showing 2 of 2 trials
NCT05766514Phase 2
Trial of Cladribine and Low-Dose Cytarabine (LoDAC) Alternating With Decitabine vs. Hypomethylating Agents (HMA) Plus Venetoclax as Frontline Therapy for AML or High-Grade MDS in Patients Unfit for Intensive Induction
NCT05841771Phase 2
Hypomethylating Agent and Venetoclax After Allo-HSCT in Patients With High-risk Myeloid Malignancies.
All 2 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 2